Current partners
Vernalis has a number of potentially high-value drug development programmes in partnership at present. These include candidates in oncology, pain therapeutics, and disorders of the central nervous system. Current partnered programmes are as follows:
| Item | Indications | Partner | Status |
| AUY922 | Cancer | Novartis | Clinical proof of concept in 2010 |
| HSP 990 | Cancer | Novartis | Phase I clinical |
| CHR-2797 | Cancer | Chroma Therapeutics | Phase II clinical |
| RPL554 | Asthma, allergic rhinitis | Verona Pharma | Phase IIa clinical |
Product Pipeline
See at a glance what Vernalis has in development
Partnership opportunities
If you are interested in working with Vernalis, please see our out-licensing and research collaboration pages for details of candidates currently available for partnership, and news of other collaborative possibilities.